Disruption, Fast and Slow
Chris Gibson, the CEO and co-founder of Recursion Pharmaceuticals, may have captured the essence of the difference in mindset between tech VCs and life science...Read More 
Share:
Your Edge in Biotech.
About David Shaywitz
David Shaywitz, MD PhD is a contributing writer for Timmerman Report.
Focus: the transformational opportunities and implementation challenges presented by emerging technologies in healthcare, biomedical discovery, and biopharmaceutical development, from NGS and cell therapies to digital biomarkers and the meaningful application of AI. Co-author (with Lisa Suennen): Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology? (Hyperink Press, 2014).
Background: physician-scientist+management consultant, experience in drug development, strategic and commercial planning, tech+health.
Job: I am Senior Partner, Takeda Ventures, Inc. (corporate/strategic VC focused on early-stage life science), and retain equity interest in DNAnexus from previous Chief Medical Officer role.
Other: I maintain a relationship with the Department of Biomedical Informatics, Harvard Medical School; I am also an Adjunct Scholar, American Enterprise Institute. Twitter: @DShaywitz (broadcast only; I do not engage on the platform). Views=my own, and may not represent the views of any organization with which I’m affiliated. For additional info, please see my personal website here.
Latest Contributions
Tech VCs and Biotech VCs: Talking Past Each Other on AI Drug Discovery
[Editor’s Note: this is a new column called “Astounding HealthTech” by TR contributor David Shaywitz.] If you want to know the difference between tech venture...Read More
Share:
Life After Twitter
[Editor’s Note: David Shaywitz is a Palo Alto-based life science VC. He used to be active on Twitter. I asked him to share his reflections...Read More
Share: